@article {46069,
	title = {Supramolecular synthon hierarchy in sulfonamide cocrystals with syn-amides and N-oxides},
	journal = {IUCRJ},
	volume = {6},
	year = {2019},
	month = {JUL},
	pages = {751-760},
	type = {Article},
	abstract = {<p>Sulfonamide drugs are well known antibacterial and antimicrobial molecules for pharmaceutical development. Building a library of suitable supramolecular synthons for the sulfonamide functional group and understanding their crystal structures with partner coformer molecules continues to be a challenge in crystal engineering. Although a few sulfonamide cocrystals with amides and N-oxides have been reported, the body of work on sulfonamide synthons is limited compared with those that have carboxylic acids and carboxamides. To address this structural gap, the present work is primarily focused on sulfonamide-lactam and sulfonamide-syn-amide synthons with drugs such as celecoxib, hydrochlorothiazide and furosemide. Furthermore, the electrostatic potential of previously reported cocrystals has been recalculated to show that the negative electrostatic potential on the lactam and syn-amide O atom is higher compared with the charge on carboxamide and pyridine N-oxide O atoms. The potential of sulfonamide molecules to form cocrystals with syn-amides and lactams are evaluated in terms of the electrostatic potential energy for the designed supramolecular synthons.</p>
},
	keywords = {cocrystals, crystal engineering, sulfonamides, supramolecular synthons, syn-amides},
	issn = {2052-2525},
	doi = {10.1107/S2052252519005037},
	author = {Bolla, Geetha and Nangia, Ashwini}
}
@article {49462,
	title = {Development of new N -{4-[(7-Chloro-5-methylpyrrolo[2,1-f ] [1,2,4]triazin-4-yl)oxy]-3-fluorophenyl}benzenesulfonamide analogues: exploring anticancer potential through MerTK inhibition},
	journal = {Synlett},
	volume = {36},
	year = {2025},
	month = {MAR},
	pages = {522-530},
	type = {Article},
	abstract = {<p>
	Mer proto-oncogene tyrosine-protein kinase (MerTK), a part of the TAM (TYRO3, AXL, and MerTK) family, is directly correlated with metastasis and various types of cancers. The inhibition of this receptor is a promising strategy for more-effective chemotherapy. Considering the pharmacophoric features of the active domain of MerTK and the structural characteristics of the investigational drug BMS794833, we designed five new N -{4-[(7-chloro-5-methylpyrrolo[2,1- f ][1,2,4]triazin-4-yl)oxy]-3-fluorophenyl}benzenesulfonamide analogues. In cytotoxicity studies, one of the analogues displayed a significantly higher cytotoxicity than cisplatin. It showed IC50 values of 2.09, 1.96, and 3.08 mu M against A549, MCF-7, and MDA-MB-231 cancer cell lines, respectively. In drug metabolism and pharmacokinetic studies, it was the most stable analogue and displayed a moderate MerTK inhibitory potential. Molecular-docking studies were performed to corroborate the MerTK inhibition, and the same analogue achieved the most significant docking score (-12.33 kcal/mol). Docking interactions demonstrated that the imine and amine group of the 3-chloropyridine moiety of BMS794833 formed hydrogen bonds with the main chain of the ATP pocket residue Met674, while the oxygen atoms of the 4-oxo-1,4-dihydropyridine-3-carboxamide moiety established hydrogen bonds with the Lys619 and Asp741 amino acid residues of the allosteric pocket of MerTK protein. These promising results provide evidence that the N -{4-[(7-chloro-5-methylpyrrolo[2,1- f ][1,2,4]triazin-4-yl)oxy]-3-fluorophenyl}benzenesulfonamide pharmacophore can give potential insights into the development of new MerTK inhibitors.</p>
},
	keywords = {cancer chemotherapeutics, kinase inhibitors, metabolic studies, pyrrolotriazines, sulfonamides},
	issn = {0936-5214},
	doi = {10.1055/a-2360-6586},
	author = {Sathe, Balaji Dashrath and Meenakshi, Meenakshi and Murti, Yogesh and Mane, Madhav Shivaji and Pandey, Sarvesh Kumar and Mahajan, Shriya and Rawat, Pramod and Kandhari, Harsimrat and Goel, Kapil Kumar and Dwivedi, Ashish Ranjan and Rathod, S. V.}
}
